Azenta, Inc. operates as a critical, albeit often behind-the-scenes, enabler within the vast and intricate world of life sciences. Having shed its former identity as Brooks Automation, a semiconductor automation firm, in 2021-2022, the company fully embraced its role as a pure-play life sciences entity, focusing on the meticulous handling and analysis of biological and chemical samples. Essentially, Azenta provides the sophisticated infrastructure and services that ensure the precious, often irreplaceable, raw materials of scientific discovery—think DNA, RNA, proteins, and cell lines—are managed with the precision of a neurosurgeon performing a delicate operation, but on a global scale. This involves a comprehensive suite of products and services across two main segments: Sample Management Solutions and Multiomics.

The Sample Management Solutions segment offers automated cryogenic storage systems capable of maintaining samples at temperatures down to a chilly -190°C, alongside outsourced repository services, cold-chain logistics, and a plethora of lab consumables and automation instruments, such as high-tech tube sealers and cappers. Meanwhile, its Multiomics segment, often operating under the GENEWIZ brand, delves into the genetic code itself, providing next-generation sequencing, gene synthesis, and other genomic analysis services that help researchers decipher the biological blueprints of life. Azenta’s business model is a hybrid, generating revenue from recurring storage fees, per-sample analysis charges, and the sale of its specialized equipment and consumables.

Operating globally with a significant footprint across North America, Europe, and Asia, Azenta serves pharmaceutical, biotechnology, academic, and government research institutions. Its competitive advantage lies in its integrated approach, combining robust automation, cryogenic expertise, and comprehensive genomic services, creating substantial switching costs for clients who entrust their invaluable biological collections to its care. However, the path hasn't been without its scientific hiccups; the company recently underwent a restructuring of its North American Multiomics labs, including workforce reductions, to streamline operations, following earlier challenges with the integration and subsequent divestiture of B Medical Systems. Furthermore, the company faced investor scrutiny in May 2026 after revising its FY2026 guidance, highlighting the inherent complexities and execution demands in this high-stakes industry. In essence, Azenta ensures that when scientists finally achieve that "eureka!" moment, the critical samples underpinning their breakthrough haven't mysteriously vanished or thawed into a puddle of scientific regret.